Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, shared on X:
“WCLC24 abstracts titles.
Presidential 2, Xiuning Le.
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations.”
Additional information.
Source: Hidehito Horinouchi/X